+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


IVIG Market: By Application, By Route of Administration, By Geography - Forecast 2016-2021

  • ID: 3974151
  • Report
  • February 2016
  • 137 pages
  • IndustryARC
1 of 3
Immunoglobulin refers to the breakdown of blood plasma that contains antibody and Intravenous immunoglobulin (IVIG) can be defined as a blood product administered intravenously. This therapy applicable for individuals who cannot produce adequate amount of antibodies. Intravenous immunoglobulin therapy helps patients with common variable immunodeficiency, Wiskott Aldrich Syndrome, X-linked agammaglobulinemia and other forms of hypogammaglobulinemia.

This report identifies the intravenous immunoglobulin market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to intravenous immunoglobulin market.

Globally North America dominated the market for intravenous immunoglobulin in 2015 with highest market share due to higher awareness about intravenous immunoglobulin coupled with developed medical and healthcare establishment in the region. North America was followed by Europe and Asia-Pacific as the second and third largest regional market respectively, for intravenous immunoglobulin. However, Asia-Pacific is expected to be fastest growing regional segment during the period of study due to fast growing healthcare setup in the region especially in India and China along with growing intravenous immunoglobulin therapy in this region.

This report on global intravenous immunoglobulin covers different applications of intravenous immunoglobulin therapy, and also classifies the global intravenous immunoglobulin market based on the basis of route of administration and clinical trial phase and market size in various geographical regions.

On the basis of delivery method of the intravenous immunoglobulin, this report is segmented into two major segments as follows: Intravenous, Subcutaneous
This reports is also classified on the basis of applications of intravenous immunoglobulin therapy, based on this global intravenous immunoglobulin therapy market is classified into ten major segments as follows: Hypogammaglobulinemia, CIDP, Immunodeficiency diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome and others
This report also covers intravenous immunoglobulin therapy market on the basis of clinical trial outlooks, major segments covered in this report are as follows: IgG, IgA, IgM, IgE and IgD
This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for intravenous immunoglobulin in each of the region.

This report identifies all the major companies operating in the global intravenous immunoglobulin market. Some of the major companies’ profiles in detail are as follows:

Baxter International Inc.

China Biologics Products, Inc.

Biotest AG
Octapharma AG
LFB Biotechnologies
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Intravenous Immunoglobulin – Market Overview

2. Executive Summary

3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis

4. Intravenous Immunoglobulin – Market Forces
4.1. Drivers
4.1.1. Rising reported of immunodeficiency diseases
4.1.2. Increasing penetration of immunoglobulin replacement therapy
4.2. Restraints
4.2.1. Cost of IVIG therapy
4.3. Opportunities
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Intravenous Immunoglobulin – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Intravenous Immunoglobulin Market, By Application
6.1. Hypogammaglobulinemia
6.2. CIDP
6.3. Immunodeficiency diseases
6.4. Congenital AIDS
6.5. Chronic Lymphocytic Leukemia
6.6. Myasthenia Gravis
6.7. Multifocal Motor Neuropathy
6.8. ITP
6.9. Kawasaki Disease
6.10. Guillain-Barre Syndrome
6.11. Others

7. Intravenous Immunoglobulin Market, By Route of Administration
7.1. Intravenous
7.2. Subcutaneous

8. Intravenous Immunoglobulin Market, By Clinical Trial Phase
8.1. IgG
8.2. IgA
8.3. IgM
8.4. IgE
8.5. IgD

9. Intravenous Immunoglobulin Market, By Geography
9.1. Europe
9.1.1. Germany
9.1.2. France
9.1.3. Italy
9.1.4. Spain
9.1.5. Russia
9.1.6. U.K.
9.1.7. Rest of Europe
9.2. Asia Pacific
9.2.1. China
9.2.2. India
9.2.3. Japan
9.2.4. South Korea
9.2.5. Rest of Asia-Pacific
9.3. North America
9.3.1. U.S.
9.3.2. Canada
9.3.3. Mexico
9.4. Rest of the World (RoW)
9.4.1. Brazil
9.4.2. Rest of RoW

10. Intravenous Immunoglobulin – Market Entropy
10.1. Expansion
10.2. Technological Developments
10.3. Merger & Acquisitions, and Joint Ventures
10.4. Supply- Contract

11. Company Profiles (By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
11.1. Baxter International Inc.
11.2. China Biologics Products, Inc.
11.3. Biotest AG
11.4. Octapharma AG
11.5. LFB Biotechnologies
11.6. Grifols SA
11.7. Kedrion Biopharma
11.8. Changchun Bio
11.9. CSL Behring
11.10. Hualan Biological Engineering Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

12. Appendix
12.1. Abbreviations
12.2. Sources
12.3. Research Methodology
12.4. Expert Insights
Note: Product cover images may vary from those shown
3 of 3


4 of 3